Search Within

Antonio Marra

Formats
  1. Journal Article (27)
  2. Meeting Abstract (16)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Sloan Kettering Institute Postdocs (45)
  2. Department of Pathology and Laboratory Medicine (34)
  3. GSK Faculty (33)
  4. Department of Medicine (31)
  5. Solid Tumor Oncology Division (31)
  6. Graduate Medical Education (24)

More Groups

People
  1. Jorge Reis-Filho (29)
  2. Pier Selenica (25)
  3. Britta Weigelt (21)
  4. Fresia Pareja Zea (19)
  5. Andrea Gazzo (17)
  6. Hannah Wen (15)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (1)
Publications
  1. Annals of Oncology (6)
  2. Journal of Clinical Oncology (6)
  3. Modern Pathology (5)
  4. Laboratory Investigation (4)
  5. Cancer Discovery (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. Nature Publishing Group (8)
  2. Oxford University Press (7)
  3. American Association for Cancer Research (6)
  4. American Society of Clinical Oncology (6)
  5. Nature Research (5)
  6. Elsevier Inc. (4)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma
    Journal Article

    Rios-Doria, E.; Momeni-Boroujeni, A.; Friedman, C. F.; Selenica, P.; Zhou, Q.; Wu, M.; Marra, A.; Leitao, M. M. Jr; Iasonos, A.; Alektiar, K. M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Research Letter

    Zattarin, E.; Presti, D.; Mariani, L.; Sposetti, C.; Leporati, R.; Menichetti, A.; Corti, C.; Benvenuti, C.; Fucà, G.; Lobefaro, R.; more...
    npj Breast Cancer (2023)

    Fulltext@MSK | Save
  • Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
    Journal Article

    Choudhury, N. J.; Marra, A.; Sui, J. S. Y.; Flynn, J.; Yang, S. R.; Falcon, C. J.; Selenica, P.; Schoenfeld, A. J.; Rekhtman, N.; Gomez, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations
    Journal Article

    Mandelker, D.; Marra, A.; Mehta, N.; Selenica, P.; Yelskaya, Z.; Yang, C.; Somar, J.; Mehine, M.; Misyura, M.; Basturk, O.; more...
    npj Precision Oncology (2023)

    Fulltext@MSK | Save
  • High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer
    Journal Article

    Ashley, C. W.; Selenica, P.; Patel, J.; Wu, M.; Nincevic, J.; Lakhman, Y.; Zhou, Q.; Shah, R. H.; Berger, M. F.; Da Cruz Paula, A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Meeting Abstract

    Liu, B.; Drago, J. Z.; Rao, Y.; Pereira, P. R.; Safonov, A.; Marra, A.; Ahmed, M. S.; Modi, S.; Reis, J. S.; Montemurro, F.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
    Meeting Abstract

    Morganti, S.; Marra, A.; Venetis, K.; Sajjadi, E.; Ascione, L.; Corti, C.; Zagami, P.; Ivanova, M.; Zattoni, L.; Curigliano, G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Meeting Abstract

    Vernieri, C.; Zattarin, E.; Mariani, L.; Menichetti, A.; Leporati, R.; Ligorio, F.; Fuca, G.; Lobefaro, R.; Griguolo, G.; Sirico, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Marra, A.; Gazzo, A.; Gupta, A.; Selenica, P.; Da Silva, E. M.; Pareja, F.; Pei, X.; Zhu, Y.; Razavi, P.; Safonov, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers
    Meeting Abstract

    Marra, A.; Goldfinger, M.; Millar, E.; Hanna, M.; Rothrock, B.; Lee, M.; Wang, Y.; van Eck, A.; Tydlitatova, L. T.; Sue, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save